LYEL
NASDAQ
$12.92
Lyell Immunopharma Inc (LYEL)
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $37.17 (+187.69%)
Market Cap
$333M
Free Cash Flow Yield
-40.41%
Beta (5Y)
1.46
Price Chart
Valuation
Market Cap$333M
P/S11272.00
P/B1.20
Profitability
Total Revenue (TTM)$31K
Gross Profit (TTM)$31K
EBITDA-$246M
Operating Margin-2213050%
EPS-$12.55
Financial Health
Free Cash Flow Yield-40.41%
Growth & Risk
Beta (5Y)1.46
Sharpe Ratio0.73